Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
66.54
-1.64 (-2.41%)
At close: May 29, 2026, 4:00 PM EDT
66.65
+0.11 (0.17%)
After-hours: May 29, 2026, 7:31 PM EDT
Halozyme Therapeutics Analyst Ratings
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $70 | Hold | Maintains | $70 | +5.20% | May 20, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $75 | Hold | Maintains | $75 | +12.71% | May 14, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $93 → $66 | Buy | Reiterates | $93 → $66 | -0.20% | May 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 | Buy | Reiterates | $95 | +42.77% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $96 | Buy | Maintains | $96 | +44.27% | May 11, 2026 |
| Benchmark Co. | Benchmark Co. | Buy Maintains $75 → $90 | Buy | Maintains | $75 → $90 | +35.26% | Feb 19, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jan 8, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Downgrades $56 | Sell | Downgrades | $56 | -15.84% | Dec 4, 2025 |